SunPharm's DENSPM and DEHOP for cancer and AIDS-related diarrhea in Phase I studies.
SUNPHARM POLYAMINE ANALOGS IN PHASE I CLINICALS FOR CANCER and AIDS-related chronic diarrhea, SunPharm reported Feb. 7. The Jacksonville, Fla.-based small molecule R&D firm has a total of 11 compounds in its pipeline of novel polyamine analogs, licensed exclusively worldwide from SunPharm's primary research facility at the University of Florida-Gainesville. UFL's Raymond Bergeron, MD, is the innovator of the polyamine analog technology.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth